EGFR L861Q
|
NSCLC
|
EGFR L861Q
|
NSCLC
|
afatinib Sensitive: B - Late Trials
|
afatinib Sensitive: B - Late Trials
|
EGFR L861Q
|
NSCLC
|
EGFR L861Q
|
NSCLC
|
gefitinib Sensitive: B - Late Trials
|
gefitinib Sensitive: B - Late Trials
|
EGFR L861Q
|
Lung Non-Small Cell Squamous Cancer
|
EGFR L861Q
|
Lung Non-Small Cell Squamous Cancer
|
EGFR inhibitor Sensitive: B - Late Trials
|
EGFR inhibitor Sensitive: B - Late Trials
|
EGFR L861Q
|
LUAD
|
EGFR L861Q
|
LUAD
|
osimertinib Sensitive: C2 – Inclusion Criteria
|
osimertinib Sensitive: C2 – Inclusion Criteria
|
EGFR L861Q
|
NSCLC
|
EGFR L861Q
|
NSCLC
|
erlotinib Sensitive: C2 – Inclusion Criteria
|
erlotinib Sensitive: C2 – Inclusion Criteria
|
EGFR L861Q
|
NSCLC
|
EGFR L861Q
|
NSCLC
|
osimertinib Sensitive: C2 – Inclusion Criteria
|
osimertinib Sensitive: C2 – Inclusion Criteria
|
EGFR L861Q
|
NSCLC
|
EGFR L861Q
|
NSCLC
|
dacomitinib Sensitive: C2 – Inclusion Criteria
|
dacomitinib Sensitive: C2 – Inclusion Criteria
|
EGFR L861Q
|
NSCLC
|
EGFR L861Q
|
NSCLC
|
anlotinib + sintilimab Sensitive: C2 – Inclusion Criteria
|
anlotinib + sintilimab Sensitive: C2 – Inclusion Criteria
|
EGFR L861Q
|
LUAD
|
EGFR L861Q
|
LUAD
|
afatinib Sensitive: C3 – Early Trials
|
afatinib Sensitive: C3 – Early Trials
|
EGFR L861Q
|
NSCLC
|
EGFR L861Q
|
NSCLC
|
EGFR inhibitor Sensitive: C3 – Early Trials
|
EGFR inhibitor Sensitive: C3 – Early Trials
|
EGFR L861Q
|
Lung Cancer
|
EGFR L861Q
|
Lung Cancer
|
pan-ErbB inhibitor Sensitive: D – Preclinical
|
pan-ErbB inhibitor Sensitive: D – Preclinical
|
EGFR L861Q
|
Esophageal Cancer
|
EGFR L861Q
|
Esophageal Cancer
|
erlotinib Resistant: D – Preclinical
|
erlotinib Resistant: D – Preclinical
|
EGFR L861Q
|
Esophageal Cancer
|
EGFR L861Q
|
Esophageal Cancer
|
cetuximab Resistant: D – Preclinical
|
cetuximab Resistant: D – Preclinical
|
EGFR L861Q
|
Esophageal Cancer
|
EGFR L861Q
|
Esophageal Cancer
|
afatinib Sensitive: D – Preclinical
|
afatinib Sensitive: D – Preclinical
|